This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
In: cancer
Check out our new article: ‘Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors’ – OPEN ACCESS
July 19, 2024Ana M. López-Estévez, Lucía Sanjurjo, Ángela Turrero, Iker Arriaga, Nicola G.A. Abrescia, Ana Poveda, Jesús Jiménez-Barbero, Anxo Vidal, Dolores Torres, María José Alonso, Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors, Journal of Controlled Release, Volume 373, 2024, Pages 277-292, ISSN 0168-3659,
https://doi.org/10.1016/j.jconrel.2024.07.032
Check out our new OPEN ACCESS publication: ‘Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors’
March 29, 2023Shubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, Ece Tavukcuoglu, Adem Şahin, Dhrubajyoti Datta, Klaus Charisse, David Moreira Álvarez, María Isabel Loza, Alfonso Calvo, Einar Sulheim, Simon Loevenich, Geir Klinkenberg, Ruth Schmid, Muthiah Manoharan, Güneş Esendağlı, Maria Jose Alonso, ‘Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors’, Journal of Controlled Release.
Read More
DIAGBI: Theranostics of brain tumors using immuno-radiopharmaceuticals and nanotechnology
November 17, 2021María José Alonso’s Lab participates in the DIAGBI project for the early and non-invasive diagnosis of brain tumors. The main objective of DIAGBI is to develop a new technology that allows early diagnosis and non-invasive monitoring of the most aggressive brain tumors, glioblastomas, using immuno-PET techniques.
Read More
María José Alonso and Libera Bio, awarded by the US National Foundation for Cancer Research with the third prize of the 2021 Salisbury Award Competition
May 26, 2021Founded by Professor Alonso, Libera Bio is a company developing a novel delivery vector of whole monoclonal antibodies to intracellular cancer targets otherwise deemed “undruggable”. The Salisbury Award Competition is designed to catalyze and advance promising cancer research innovations onto a path of commercialization and patient impact.
Read More
Check out our OPEN ACESS article on “Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues”
March 11, 2021Nanotechnology is now opening new avenues for the treatment of cancer. Here we present a critical view on the potential of nanotechnology to improve the delivery of drugs (small molecules, monoclonal antibodies and RNA-based therapies) to tumor cells or to the tumor microenvironment. We foresee a future where the therapeutic strategy can be thoughtfully designed taking into account the tumor type, the immune status of the patient, and the nature of the active molecule. This is the era of personalized nanomedicine.
Read More
Libera Bio receives the Bioga Award for the Best Biotech Business Idea 2020
December 11, 2020Libera Bio is a spin-off of the Maria Jose Alonso’s lab at the University of Santiago de Compostela that develops anticancer drugs based on nanotechnology. The goal of its project is to address “undruggable” oncology targets by delivering whole antibodies inside the tumor and metastatic cells.
Read More